Introduction {#s1}
============

Phthalates are a group of chemicals used in multiple consumer products ([@c38]). Low-molecular-weight (LMW) phthalates are used in fragrances, cosmetics, and shampoos ([@c2], [@c3]; [@c37]), and personal care products appear to be a primary source of exposure ([@c23]; [@c25]). High-molecular-weight (HMW) phthalates are common plasticizers in products such as food packaging, building materials, medical devices, and toys ([@c25]; [@c37]). Phthalates are not covalently bound to the plastics that they soften and can easily leach into the environment ([@c13]; [@c53]). Exposure to phthalates is ubiquitous in the U.S. population ([@c18]) and occurs via ingestion, inhalation, and dermal absorption ([@c1]; [@c60]). A recent examination of five cycles of the National Health and Nutrition Examination Survey (NHANES) found that 10 different phthalate metabolites were detected in $> 70\%$ of participants between 2001 and 2010 ([@c77]).

Although phthalates have short half-lives in the body and are rapidly excreted ([@c2], [@c3], [@c4]; [@c53]), humans are chronically exposed from common consumer goods, including plastics, personal care products, and food packaging. Phthalates are endocrine disrupting chemicals (EDCs) that cross the placenta, exposing the developing fetus ([@c65]; [@c75]). The Chronic Hazard Advisory Panel of the U.S. Consumer Product Safety Commission identified fetal development as the most vulnerable target of toxicity for phthalates ([@c49]), and the nervous system may be particularly susceptible due to rapid brain development during the prenatal period. Animal and epidemiologic studies have shown that neurotoxic effects of phthalates may be mediated by antiandrogenic activity ([@c8]; [@c72]), alterations in thyroid function ([@c7]; [@c32]), and disruption of brain dopaminergic activity ([@c5]; [@c68]).

Several epidemiological studies have evaluated associations between prenatal phthalate exposure and neurodevelopmental outcomes among children followed up to age 10 ([@c12], [@c11]; [@c26]; [@c31]; [@c33]; [@c44]; [@c48]; [@c55]; [@c64]; [@c74]), with inconsistent findings that vary by phthalate metabolite and child sex ([@c13]). Although previous studies have reported associations of prenatal urinary phthalate concentrations with poorer cognition ([@c31]), social cognition ([@c55]), and executive function ([@c26]) and more internalizing and externalizing behaviors ([@c26]; [@c44]; [@c48]; [@c74]), others have found associations with improved cognitive performance ([@c11]) or null associations with social cognition outcomes ([@c12]; [@c64]).

To our knowledge, no studies have examined the associations of prenatal phthalate exposure with neurodevelopment measured longitudinally during childhood and into adolescence---information that is important for evaluating the potential long-term impact of these chemicals. We examined associations of prenatal phthalate exposure with cognition, executive function, and behavior outcomes assessed from ages 7 through 16 y in the Center for the Health Assessment of Mother and Children of Salinas (CHAMACOS) birth cohort study. We hypothesized that higher prenatal phthalate concentrations would be associated with adverse neurodevelopment during childhood and adolescence.

Methods {#s2}
=======

Study Population {#s2.1}
----------------

CHAMACOS is a longitudinal birth cohort study examining the health effects of prenatal and early life environmental exposures among Mexican-American children in California's Salinas Valley. Subject recruitment and procedures for CHAMACOS have been described elsewhere ([@c28], [@c29]). Briefly, eligible pregnant women (i.e., $\geq 18\; y\text{ \ old}$, $< 20\;{wk}$ gestation, Spanish- or English-speaking, qualified for low-income health insurance, and planning to deliver at the county hospital) were recruited in community clinics between September 1999 and December 2000. Of the 601 women initially enrolled, 527 (88%) remained in the study and delivered a live-born singleton.

We conducted interviews with mothers at two prenatal study visits ($\text{median} = 13$ and 26 wk gestation), shortly after delivery, and when children were age 6 months, and 1, 2, 3.5, 5, 7, 9, 10.5, 12, 14, and 16 y. We also assessed CHAMACOS children's growth and development from ages 6 months to 16 y. We restricted current analyses to children born to mothers with measures of prenatal urinary phthalate metabolites who completed at least one neurodevelopmental assessment at age 7 ($n = 322$), 9 ($n = 319$), 10.5 ($n = 307$), 12 ($n = 322$), 14 ($n = 312$), or 16 y ($n = 300$). In total, 334 children (56% of the initial cohort) had prenatal phthalate data and completed at least one assessment included in these analyses (total sample size exceeds sample size at any individual time point because some participants only completed tests at one time point; 334 unique participants provided usable data from at least one visit).

The University of California Berkeley Committee for the Protection of Human Subjects approved all study activities, and we obtained written informed consent from all mothers. We also obtained child verbal assent at age 7, 9, and 10.5 y, and child written assent at age 12, 14, and 16 y. The Centers for Disease Control and Prevention (CDC) deferred to the University of California Berkeley IRB as the IRB of record.

Neurodevelopmental Outcomes {#s2.2}
---------------------------

Bilingual, bicultural psychometricians, trained and supervised by a clinical neuropsychologist, administered neuropsychological tests and computer-based tasks in the child's dominant language in a quiet room free from distraction. We obtained additional information on children's behavior across multiple settings with rating scales administered to the parent at all study visits (7, 9, 10.5, 12, 14 and 16 y), the teacher at the 7-y visit, and the child (self-report) at the 10.5-, 14-, and 16-y visits. Outlined below are the instruments we used to assess cognition, executive function, social cognition, and behavior in CHAMACOS children.

Executive Function {#s2.3}
------------------

### Behavior Rating Inventory of Executive Function (BRIEF) ([@c35]). {#s2.3.1}

Parents of CHAMACOS children completed the BRIEF when their children were age 7, 9, and 12 y. Teachers completed the BRIEF when children were 7 y old. We examined age- and sex-standardized scores (*T*-scores; $M = 50$, $\text{SD} = 10$) across two indices (the Behavioral Regulation Index and the Metacognition Index) and one summary score (Global Executive Composite).

### NEPSY tower ([@c45]). {#s2.3.2}

At age 9, children completed the NEPSY tower, which assesses planning, monitoring, self-regulation, and problem solving and yields a single scaled score ($M = 10$, $\text{SD} = 3$).

### Wisconsin Card Sort Task-64: Computer version 2 -- research edition (WCST) ([@c39]). {#s2.3.3}

At ages 9 and 12 y, children completed the WCST, a computerized test that measures skills around strategic planning, ability to shift cognitive strategies, and impulse control. We examined *T*-scores for errors and perseverative errors ($M = 50$, $\text{SD} = 10$).

Cognition {#s2.4}
---------

### Weschler Intelligence Scale for Children, fourth edition (WISC-IV) ([@c73]). {#s2.4.4}

Study staff administered the WISC-IV at the 7- and 10.5-y study visits. Children were administered the WISC-IV in English (33.3% of participants) or Spanish (66.7% of participants) at age 7 y. All children were tested in English at age 10.5 y. We calculated scores for Full-Scale IQ (FSIQ) and four subscales: Verbal Comprehension (VCIQ), Perceptual Reasoning (PRIQ), Working Memory (WMIQ), and Processing Speed (PSIQ). We standardized scores against U.S. population-based norms for English- and Spanish-speaking children ($M = 100$, $\text{SD} = 15$).

Social Cognition {#s2.5}
----------------

### Evaluación neuropsicológica del niño (ENI) ([@c52]). {#s2.5.5}

Children completed the ENI at age 9 y. In this test, children were shown eight different photographs and scored on how well they identified the mental state of others (e.g., happy, sad, angry, scared). Participants received a score of 1 for correctly identifying the expression and a score of 0 for incorrectly identifying the expression ($\text{maximum} = 8\text{ \ points}$).

### NEPSY-II Affect Recognition subtest ([@c46]). {#s2.5.6}

Children completed the NEPSY-II Affect Recognition at age 12 y. In this test, children had to: *a*) identify whether two photographs depicted faces with the same affect; *b*) select two faces with the same affect from three to four photographs; *c*) select one of four faces that depicted the same affect as the face at the top of the page; and *d*) view a photograph of a face briefly and select two faces that depicted the same affect as the face previously viewed. Participants received a score of 1 for correctly identifying the expression and a score of 0 for incorrectly identifying the expression ($\text{maximum} = 35\text{ \ points}$).

### Social Responsiveness Scale, version 2 (SRS-2) ([@c21]). {#s2.5.7}

At the 14-y visit, parents completed the SRS-2, a 65-item rating scale developed to assess quantitative traits related to Autism Spectrum Disorder (ASD) in population-based samples ([@c21]). Parents were asked the frequency that their child exhibited specific behaviors, such as avoiding social behavior with peers or adults, over the previous 6 months ($1 = \text{not\  \ true}$, $2 = \text{sometimes\  \ true}$, $3 = \text{often\  \ true}$, and $4 = \text{almost\  \ always\  \ true}$), and we computed sex-standardized SRS total *T*-scores ($M = 50$, $\text{SD} = 10$).

Attention and Behavior {#s2.6}
----------------------

### Behavior Assessment System for Children, second edition (BASC-2) and Self-Report of Personality (SRP) ([@c59]). {#s2.6.8}

Parents completed the BASC-2 when children were age 7, 10.5, 14, and 16 y. Teachers completed the BASC-2 when children were 7 y old. Children completed specific scales of the BASC-2 Self-Report of Personality (SRP) at 10.5 and 14 years of age and completed a full SRP at 16 years of age. We examined parent- and teacher-reported scores from four individual scales (hyperactivity, attention problems, depression, and anxiety) and two composite scales (internalizing and externalizing problems). We examined self-reported scores for the internalizing problems composite scale (there was no externalizing composite score for the SRP) and the hyperactivity, attention problems, depression, and anxiety subscales. BASC-2 data were examined as age- and sex-standardized *T*-scores ($M = 50$, $\text{SD} = 10$).

###### 

Sociodemographic characteristics \[*n* (%) or median (P25--P75)\] of live-born singletons from the initial CHAMACOS mother--child cohort ($n = 527$) and study participants with prenatal urinary phthalate metabolites who completed at least one of the neurobehavioral assessments at ages 7 ($n = 322$).[^*a*^](#TF2){ref-type="table-fn"}

Table 1 lists characteristics in the first column; the corresponding number of live-born singletons N(%) or median (P25-P75) and children with prenatal phthalates and at least one assessment at 7Y visit N(%) or median (P25-P75) are listed in the other columns.

  Characteristic                                                Live-born singletons $n$ (%) or Median (P25--P75)   Children with prenatal phthalates and at least one assessment at 7-y visit $N$ (%) or Median (P25--P75)
  ------------------------------------------------------------- --------------------------------------------------- ---------------------------------------------------------------------------------------------------------
  *Maternal/household characteristics*                                                                              
  Age at enrollment (y)                                         25 (22--29)                                         25.5 (22--29)
  Education                                                                                                         
   $\leq 6\text{th}$ grade                                      228 (43.3)                                          142 (44.1)
   7th--12th grade                                              192 (36.4)                                          110 (34.2)
   Completed high school                                        107 (20.3)                                          70 (21.7)
  Receptive vocabulary (PPVT score) at 9-y visit                                                                    98 (80--108)
   Missing ($n$)[^*b*^](#TF3){ref-type="table-fn"}              ---                                                 23
  Country of birth                                                                                                  
   Mexico                                                       444 (84.3)                                          277 (86.0)
   Other                                                        83 (15.8)                                           45 (14.0)
  Years in U.S.                                                                                                     
   $\leq 5$                                                     270 (51.2)                                          151 (46.9)
   6--10                                                        115 (21.8)                                          84 (26.1)
   $\geq 11$                                                    142 (27.0)                                          88 (27.0)
  Parity                                                                                                            
   0                                                            180 (34.2)                                          102 (31.7)
   $\geq 1$                                                     347 (65.8)                                          220 (68.3)
  Smoking during pregnancy                                                                                          
   No                                                           496 (94.1)                                          309 (96.0)
   Yes                                                          31 (5.9)                                            13 (4.0)
  Maternal depression at 9-year visit ($\geq 16$ CES-D score)                                                       
   No                                                           225 (42.7)                                          233 (72.4)
   Yes                                                          78 (14.8)                                           81 (25.1)
   Missing ($n$)[^*b*^](#TF3){ref-type="table-fn"}              224 (42.5)                                          8 (2.5)
  Household income at 10.5-year visit                                                                               
   At or below poverty level                                    242 (45.9)                                          225 (69.9)
   Above poverty level                                          95 (18.0)                                           97 (30.1)
   Missing ($n$)[^*b*^](#TF3){ref-type="table-fn"}              190 (36.1)                                          0 (0.0)
  *Child characteristics*                                                                                           
  Child's sex                                                                                                       
   Boy                                                          263 (49.9)                                          153 (47.5)
   Girl                                                         264 (50.1)                                          169 (52.5)
  Birth weight (grams)                                          3,440 (3,155--3,780)                                3,437.5 (3,170--3,785)
  Gestational age at delivery (wk)                              39 (38--40)                                         39 (38--40)
  Breastfeeding duration (months)                                                                                   
   $\leq 6$                                                     311 (59.0)                                          163 (50.6)
   $> 6$                                                        205 (38.9)                                          159 (49.4)
   Missing                                                      11 (2.1)                                            0 (0.0)
  Age at assessment (y)                                                                                             
   7-y assessment                                               ---                                                 7.0 (7.0, 7.1)
  Language of assessment                                                                                            ---
   English                                                      ---                                                 106 (33.8)
   Spanish                                                      ---                                                 208 (66.2)
  HOME Score Assessment                                                                                             0.1 ($- 0.6–0.8$)
   Missing ($n$)[^*b*^](#TF3){ref-type="table-fn"}              ---                                                 ---

Note: ---, no data; CES-D, Center for Epidemiologic Studies Depression Scale; $n$, number of study participants; PPVT, Peabody Picture Vocabulary Test.

At age 7, a total of 322 mothers and 314 youth completed at least one neurodevelopmental assessment.

Missing data for children followed-up were imputed with values collected on these variables at earlier or later time points for all analyses.

### Conners' Attention Deficit Hyperactivity Disorder (ADHD)/DSM-IV Scales, parent versions (CADS) ([@c19]). {#s2.6.9}

Parents completed the CADS when children were ages 7, 9, and 12 y old. Teachers completed the CADS at the 7-y study visit. We computed age- and sex-standardized *T*-scores for the four CADS subscales (Conners' ADHD index, and DSM-IV-based inattentive, hyperactive/impulsive subscales, and total ADHD) ($M = 50$, $\text{SD} = 10$).

### Conners' Continuous Performance Test, version 5 (CPT II) ([@c20]). {#s2.6.10}

At 9 and 12 years of age, children completed the CPT-II, a computerized test that assesses hit rate, accuracy, and impulse control. We examined sex- and age-standardized *T*-scores ($M = 50$, $\text{SD} = 10$) for errors of commission (false positives), errors of omission (false negatives), and continuous ADHD Confidence Index score. The ADHD Confidence Index score indicates the probability that children are correctly classified as having clinical ADHD.

Phthalate Exposure Assessment {#s2.7}
-----------------------------

Mothers provided spot urine samples in polypropylene containers at each of the two prenatal study visits ($\text{median} = 13$ and 26 wk gestation) ($n = 590$). After collection, study staff aliquoted urine into glass vials and stored them at $- 80{^\circ}C$ until shipment on dry ice to the CDC for analysis. Urine samples were analyzed with online solid phase extraction--isotope-dilution high-performance liquid chromatography--electrospray ionization-tandem mass spectrometry ([@c66]) to quantify concentrations of 11 phthalate metabolites from eight parent compounds: monoethyl phthalate \[MEP, metabolite of diethyl phthalate (DEP)\]; mono-n-butyl phthalate \[MBP, metabolite of di-*n*-butyl phthalate (DnBP)\]; monoisobutyl phthalate \[MiBP, metabolite of diisobutyl phthalate (DiBP)\]; monobenzyl phthalate \[MBzP, metabolite of butylbenzyl phthalate (BBzP)\]; four metabolites of di(2-ethylhexyl) phthalate (DEHP): \[mono(2-ethylhexyl) phthalate (MEHP), mono (2-ethyl-5-hydroxyhexyl) phthalate (MEHHP), mono(2-ethyl-5-oxohexyl) phthalate (MEOHP), and mono(2-ethyl-5-carboxypentyl) phthalate (MECCP)\]; mono(carboxyoctyl) phthalate \[MCOP, metabolite of diisononyl phthalate (DiNP)\]; mono(carboxynonyl) phthalate \[MCNP, metabolite of diisodecyl phthalate (DiDP)\]; and mono-3-carboxypropyl phthalate (MCPP, metabolite of several HMW phthalates and a minor metabolite of DBP). Quality control procedures included the use of laboratory, calibration standards, and quality controls of high and low concentrations. Limits of detection (LODs) ranged from 0.2 to $0.6\text{ \ ng}/{mL}$ for individual metabolites.

###### 

Distribution of phthalate biomarker concentrations (specific-gravity-corrected) measured in maternal urine samples collected at two time points during pregnancy, CHAMACOS ($n = 327$).

Table 2 lists phthalate biomarker in the first column; the corresponding percentage of L O D for the first and the second measurements are listed further. Values for sigma squared sub btw, sigma squared sub within and ICC are listed in the adjacent columns. Further, values for the average of two measurements with respect to GM (GSD), minimum, P25, P50, P75, and maximum are listed in the other columns.

  Phthalate biomarker[^*a*^](#TF5){ref-type="table-fn"}   \% $> LOD$   $\sigma_{btw}^{2}$[^*d*^](#TF8){ref-type="table-fn"}   $\sigma_{within}^{2}$[^*d*^](#TF8){ref-type="table-fn"}   ICC[^*d*^](#TF8){ref-type="table-fn"}   Average of two measurements                                                
  ------------------------------------------------------- ------------ ------------------------------------------------------ --------------------------------------------------------- --------------------------------------- ----------------------------- ------------- ------ ------- ------- ------- ----------
  $\Sigma\text{LMW}$                                      N/A          N/A                                                    0.94                                                      2.14                                    0.31                          1.5 (32.9)    0.1    0.7     1.4     2.9     105.7
  MEP                                                     100.0        99.7                                                   1.26                                                      2.59                                    0.33                          241.7 (3.3)   14.3   108.5   223.1   501.9   20,462.0
  MBP                                                     98.8         100.0                                                  0.30                                                      2.29                                    0.11                          28.4 (2.4)    1.3    16.2    26.8    47.6    529.8
  MiBP                                                    92.9         96.1                                                   0.65                                                      2.79                                    0.19                          3.4 (2.7)     0.1    1.8     3.3     6.7     138.0
  $\Sigma\text{HMW}$                                      N/A          N/A                                                    0.34                                                      1.27                                    0.21                          0.3 (2.1)     0.0    0.2     0.3     0.5     5.1
  MBzP                                                    98.5         98.7                                                   0.88                                                      2.01                                    0.31                          8.9 (2.6)     0.5    4.9     9.0     17.7    137.0
  MCPP                                                    88.3         93.6                                                   0.62                                                      3.02                                    0.17                          2.2 (2.3)     0.0    1.4     2.4     3.8     28.5
  MCOP                                                    96.9         96.5                                                   0.40                                                      1.83                                    0.18                          3.8 (2.1)     0.2    2.4     3.8     5.6     93.2
  MCNP                                                    95.7         96.8                                                   0.43                                                      1.46                                    0.23                          2.3 (2.0)     0.2    1.5     2.3     3.4     42.7
  $\Sigma\text{DEHP}$                                     N/A          N/A                                                    0.38                                                      1.43                                    0.21                          0.2 (2.2)     0.0    0.1     0.2     0.4     5.0
  MEHP                                                    88.6         92.0                                                   0.59                                                      2.80                                    0.17                          4.5 (2.6)     0.2    2.6     4.4     7.7     141.3
  MEHHP                                                   100.0        99.0                                                   0.49                                                      1.82                                    0.21                          18.9 (2.4)    0.9    11.3    17.9    32.6    458.4
  MECPP                                                   100.0        100.0                                                  0.36                                                      1.29                                    0.22                          32.4 (2.2)    4.2    20.9    31.4    49.6    631.8
  MEOHP                                                   98.2         98.7                                                   0.52                                                      2.10                                    0.20                          13.8 (2.4)    0.6    8.1     14.0    22.4    335.0

Note: ICC, intraclass correlation coefficient; LOD, limit of detection; MBP, mono-n-butyl phthalate; MBzP, monobenzyl phthalate; MCPP, mono(3-carboxypropyl) phthalate; MCOP, mono(carboxyoctyl) phthalate; MCNP, mono(carboxynonyl) phthalate; MECCP, mono(2-ethyl-5-carboxypentyl) phthalate; MEHP, mono-2-ethylhexyl phthalate; MEHHP, mono(2-ethyl-5-hydroxyhexyl) phthalate; MEOHP, mono(2-ethyl-5-oxohexyl) phthalate; MEP, monoethyl phthalate; MiBP, mono-isobutyl phthalate; $\Sigma\text{DEHP}$, sum of di-2-ethylhexyl phthalate metabolites; $\Sigma\text{HMW}$, sum of high-molecular-weight phthalate metabolites; $\Sigma\text{LMW}$, sum of low-molecular-weight phthalate metabolites.

Units are ng/mL for all individual metabolites and nmol/mL for the sums of metabolites ($\Sigma\text{DEHP}$, $\Sigma\text{HMW}$, $\Sigma\text{LMW}$).

Median (range) gestational age at $\text{urine\  \ collection} = 12.9$ (5.3--28.5) weeks gestation.

Median (range) gestational age at $\text{urine\  \ collection} = 26.3$ (21.8--39.5) weeks gestation.

Variances between- and within-woman and ICC were calculated and reported for $\log_{2}\text{-transformed}$ specific-gravity adjusted urinary phthalate concentrations (nonaveraged).

Covariate Data Collection {#s2.8}
-------------------------

Study staff administered structured questionnaires to mothers at each study visit to collect information on a variety of factors, including maternal and child demographics; maternal parity; prenatal diet and smoking, alcohol and illicit drug use; mode of delivery; duration of breastfeeding; parental marital status, maternal education, and employment; and household income. We administered the Peabody Picture Vocabulary Test (PPVT)-Revised ([@c22]) to estimate maternal receptive vocabulary (6-month and 9-y study visits), the Center for Epidemiologic Studies Depression Scale (CES-D) ([@c58]) to assess maternal depression (1-, 3-, 7-, and 9-y visits), and the Home Observation for the Measurement of the Environment-Short Form (HOME-SF) ([@c15]) to assess enrichment in the home (6-month, 1-, 2-, 3.5-, 7-, 9-, and 10.5-y visits). We abstracted medical information, such as birth weight and gestational duration, from prenatal and delivery medical records.

We examined potential confounding by other prenatal exposures for which we have reported associations with adverse neurodevelopment in CHAMACOS, including organophosphate pesticides (OPs) ([@c9]; [@c30]; [@c51]), organochlorines (OCs) ([@c29]; [@c34]), polybrominated diphenyl ether flame retardants (PBDEs) ([@c27]; [@c61]), and manganese (Mn) ([@c56]). Detailed methods for prenatal biospecimen collection and quantification of these chemicals have been described previously ([@c10]; [@c29]; [@c27]; [@c56]). Briefly, we quantified prenatal urinary dialkyl phosphate (DAP) metabolite concentrations as a measure of OP exposure in the same two maternal pregnancy urine samples we used to measure phthalate metabolites (collected at 13 and 26 wk gestation) ([@c10]). We also measured OCs ([@c29]) and PBDEs ([@c27]) in pregnancy \[$\text{mean} \pm \text{standard\  \ deviation\  }\left( \text{SD} \right) = 26.7 \pm 2.6\;{weeks}$\] serum samples, or in maternal delivery samples for a subset of women ($\sim 10\%$) without pregnancy samples. We assessed prenatal exposure to Mn in children's deciduous teeth ([@c56]).

Statistical Analysis {#s2.9}
--------------------

We averaged phthalate biomarker concentrations across the two urine samples to better estimate exposure throughout pregnancy ([@c40]) and $\log_{2}\text{-transformed}$ to normalize the residuals and reduce the influence of the outliers. For concentrations below the LOD, we used the instrumental reading value, when available, and imputed nondetectable concentrations (without an instrumental reading) using maximum likelihood estimation following the log-normal distribution ([@c50]).

We categorized phthalate metabolites based on their similarity in chemical structure and biological activity ([@c69]) as: *a*) molar sums of metabolites of LMW ($\Sigma\text{LMW}$) phthalates (i.e., MEP, MBP, and MiBP) or of metabolites of HMW phthalates ($\Sigma\text{HMW}$) (i.e., MBzP, MCPP, MCOP, and MCNP); and *b*) the molar sum of DEHP metabolites ($\Sigma\text{DEHP}$; i.e., MEHP, MEHHP, MEOHP, and MECPP). We also looked at individual phthalate metabolites ($\mathit{n} = 11$).

We examined associations of average prenatal urinary phthalate biomarker concentrations (individual metabolites and summed concentrations) with neurodevelopmental outcomes assessed at a single time point (i.e., SRS, ENI, NEPSY-II, BASC-2 teacher-report, CADS teacher-report, and SRP internalizing scale) using multivariable linear regression and at multiple time points (i.e., WCST, BRIEF, WISC-IV, CADS, CPT-II, and other BASC-2 scales) using generalized estimating equations (GEE). If associations of phthalates with repeated measures of an outcome changed appreciably over time, we presented estimates from the linear regression analyses for each time point separately. To evaluate the presence of nonlinearity in exposure--outcome associations, we modeled phthalate concentrations categorized into tertiles.

We selected the following covariates *a priori* using a directed acyclic graph (See Figure S1): maternal age at enrollment (continuous), education (categorical: $< 6\text{th}$ grade, 7th--12th grade, completed high school), country of birth (categorical: Mexico vs. other), years in the United States (continuous), and depression status at the time of assessment (dichotomous: $< 16$ vs. $\geq 16$ points in CES-D); child sex (dichotomous) and exact age at assessment (continuous); language of assessment or language of interview for parent-reported outcomes (dichotomous); HOME z-score at time of assessment (continuous); household income at the time of assessment (categorical: at or below poverty line vs. above poverty line); and psychometrician. Because the CPT-II and WCST were computerized tasks, we additionally adjusted these outcomes for children's video game usage (average hours per week) at age 9 as reported by mothers. We imputed missing values for covariates (all $< 10\%$ missing) using data from the nearest available visit. If values for a missing covariate were not available from an earlier or later study visit, we randomly selected a value from the dataset ($n = 1$ participant missing HOME score and maternal depression values at the 14- and 16-y visits; $n = 2$ participants missing maternal PPVT for sensitivity analyses).

We evaluated effect modification of the exposure--outcome associations by child sex using an augmented product term approach ([@c14]) in which we specified a model including product terms between sex and each of the covariates, including sex. Interactions were assessed using sex-metabolite product terms from the same model and were considered statistically significant if $p < 0.10$.

We conducted sensitivity analyses to assess the robustness of our results. First, we fitted our regression models excluding preterm births ($n = 27$; defined as delivery $< 37\text{ \ weeks}$) and low birth weight (LBW) children ($n = 14$; defined as birthweight $< 2,500\text{ \ grams}$) ($n = 11$ LBW and preterm). The number of children excluded varied by neurodevelopmental test because not all study participants completed each test. Second, we adjusted our regression models for additional potential confounders \[i.e., breastfeeding duration ($< 6\text{ \ months}$ vs. $\geq 6\text{ \ months}$) and maternal receptive vocabulary at the 9-y visit (PPVT score: $\leq 74$, 75--99, $\geq 100$) by adding them individually to models. Last, we examined the confounding effects of prenatal exposure to other known neurotoxicants by adding prenatal PBDEs, DAPs, OCs, and Mn concentrations individually to our adjusted models. These additional neurotoxicants were modeled continuously and log-transformed (PBDEs, DAPs, and OCs transformed to the $\log_{10}$ scale and Mn transformed to the $\log_{2}$ scale). PBDEs were modeled as the lipid-adjusted sum of four congeners ($- 47$, $- 99$, $- 100$, $- 153$), and OCs were modeled as the lipid-adjusted sum of dichlorodiphenyltrichloroethane (*p,p′*-DDT, *o,p*′-DDT), and dichlorodiphenyldichloroethylene (*p,p*′-DDE) from maternal serum collected at 26 wk gestation. Total DAP metabolite levels were calculated as the sum of six nonspecific urinary OP metabolites, averaged across two prenatal urine samples. All levels below the LOD were set at $\text{LOD}\sqrt{2}$.

Results {#s3}
=======

[Table 1](#t1){ref-type="table"} shows the sociodemographic characteristics of mother--child pairs from the initial cohort who delivered a live-born singleton ($n = 527$) and participants with prenatal phthalate data who completed at least one neurodevelopmental test at age 7 y ($n = 322$). Table S1 shows the sociodemographic characteristics of participants with prenatal phthalate data who completed at least one neurodevelopmental test at age 9, 10.5, 12, 14, or 16 y. Among those with at least one neurodevelopmental assessment at age 7 y, most mothers were born in Mexico (86%), had not completed high school (78%), and had a family income below the U.S. poverty threshold (70%) ([Table 1](#t1){ref-type="table"}). Nearly 53% of CHAMACOS children were female, and 49% were breastfed for $> 6\text{ \ months}$ ([Table 1](#t1){ref-type="table"}). The standardized scores for each neurodevelopmental test are shown in Table S2.

Phthalate metabolites were detected in 88%--100% of samples, depending on the metabolite ([Table 2](#t2){ref-type="table"}). Phthalate metabolite concentrations were generally similar to those measured in NHANES participants around the same time period ([@c16]) (see Table S3 for uncorrected phthalate metabolite concentrations). Between-person variance exceeded within-person variance by a factor of two to eight ([Table 2](#t2){ref-type="table"}). Intraclass correlation coefficients (ICC) varied from 0.11 to 0.33 ([Table 2](#t2){ref-type="table"}). Spearman's correlation coefficients among different phthalate metabolites ranged from 0.11 to 0.98 (see Table S4).

Our analysis of tertiles provided evidence of nonlinearity for some associations, such as for $\Sigma\text{LMW}$ and $\Sigma\text{DEHP}$ with WCST executive function outcomes (see Table S5). However, given that most exposure--outcome associations were linear (see Tables S5--S11), we included phthalate biomarker concentrations parameterized as continuous variables in all models, with point estimates representing the change in outcome for each 2-fold increase in biomarker concentrations. In our main analyses, we present results for the phthalate biomarkers $\Sigma\text{LMW}$, $\Sigma\text{HMW}$, and $\Sigma\text{DEHP}$. Results for individual phthalate metabolites are included in Supplementary Material.

Executive Function {#s3.1}
------------------

Most associations between prenatal concentrations of $\Sigma\text{LMW}$, $\Sigma\text{HMW}$, and $\Sigma\text{DEHP}$ with executive function outcomes were null in both combined ([Table 3](#t3){ref-type="table"}) and sex-stratified (see Table S12) analyses. When stratified by sex, we found that higher prenatal $\Sigma\text{LMW}$ concentrations were associated with better scores for perseverative errors among boys ($\beta = 1.4$, 95% CI: 0.3, 2.5), but not among girls ($\beta = 0.1$, 95% CI: $- 0.9$, 1.1; $p\text{-int} = 0.08$; see Table S12).

###### 

Adjusted associations \[$\beta$ (95% CI)\] of prenatal urinary phthalate biomarker concentrations (nmol/mL; $\log_{2}\text{-transformed}$ and specific gravity-adjusted)[^*a*^](#TF10){ref-type="table-fn"} with executive function and cognition outcomes at 7, 9, 10.5, and/or 12 y using GEE models, CHAMACOS.

Table 3 has seven columns, namely, outcomes, orientation, n values, k values, sigma LMW, sigma HMW, and sigma DEHP.

  Outcomes                                                               Orientation[^*b*^](#TF11){ref-type="table-fn"}   $n$   *k*   $\Sigma\text{LMW}$       $\Sigma\text{HMW}$       $\Sigma\text{DEHP}$
  ---------------------------------------------------------------------- ------------------------------------------------ ----- ----- ------------------------ ------------------------ ------------------------
  *Executive function*                                                                                                                                                                  
  WCST (*T*-score) (9, 12 y)                                                                                                                                                            
   Errors                                                                ($-$)                                            593   318   0.2 ($- 0.4$, 0.8)       0.5 ($- 0.4$, 1.4)       0.5 ($- 0.3$, 1.3)
   Perseverative Errors                                                  ($-$)                                            593   318   0.7 ($- 0.1$, 1.4)       0.7 ($- 0.6$, 1.9)       0.6 ($- 0.5$, 1.8)
  BRIEF---parent report (*T*-score) (7, 9, 12 y)                                                                                                                                        
   Behavioral Regulation Index                                           ($+$)                                            923   331   0.1 ($- 0.5$, 0.6)       0.1 ($- 0.8$, 1.0)       0.0 ($- 0.9$, 0.8)
   Metacognition Index                                                   ($+$)                                            922   330   $- 0.4$ ($- 1.0$, 0.1)   $- 0.1$ ($- 1.0$, 0.9)   $- 0.1$ ($- 1.0$, 0.7)
   Global Executive Composite                                            ($+$)                                            923   331   $- 0.3$ ($- 0.8$, 0.3)   0.0 ($- 1.0$, 1.0)       $- 0.1$ ($- 1.0$, 0.8)
   NEPSY Tower (scaled score)[^*c*^](#TF12){ref-type="table-fn"} (9 y)   ($-$)                                            313   313   0.1 ($- 0.1$, 0.3)       0.1 ($- 0.2$, 0.4)       0.1 ($- 0.2$, 0.4)
  *Cognition*[^*d*^](#TF13){ref-type="table-fn"}                                                                                                                                        
  WISC-IV Full-Scale IQ (scaled scores) (7, 10.5 y)                      ($-$)                                            589   321   $- 0.2$ ($- 1.0$, 0.6)   0.0 ($- 1.4$, 1.4)       0.1 ($- 1.3$, 1.4)
   Verbal comprehension IQ                                               ($-$)                                            621   324   $- 0.4$ ($- 1.1$, 0.4)   $- 0.3$ ($- 1.6$, 1.0)   $- 0.3$ ($- 1.5$, 1.0)
   Perceptual reasoning IQ                                               ($-$)                                            621   324   0.2 ($- 0.7$, 1.2)       0.4 ($- 1.1$, 1.9)       0.3 ($- 1.1$, 1.7)
   Working memory IQ                                                     ($-$)                                            593   323   $- 0.6$ ($- 1.4$, 0.1)   $- 0.1$ ($- 1.5$, 1.2)   $- 0.1$ ($- 1.4$, 1.2)
   Processing speed IQ                                                   ($-$)                                            593   323   0.2 ($- 0.4$, 0.9)       0.5 ($- 0.7$, 1.7)       0.5 ($- 0.6$, 1.7)

Note: Models were adjusted for maternal age at enrollment, education, country of birth, years in the U.S., depression at time of assessment; child sex, child age at time of assessment, language of assessment, HOME score, and household income at time of assessment. WCST models were also adjusted for children's video game usage. BRIEF, Behavior Rating Inventory Executive Function; *k*, number of children with data for at least one time point; $n$, number of observations from all time points; NEPSY, A Developmental Neuropsychological Assessment; $\Sigma\text{LMW}$, sum of metabolites of low-molecular-weight phthalates; $\Sigma\text{HMW}$, sum of metabolites of high-molecular-weight phthalates; $\Sigma\text{DEHP}$, sum of di(2-ethylhexyl) phthalate metabolites; WCST, Wisconsin Card Sort Task-64: computer version 2---research edition; WISC-IV, Wechsler Intelligence Scale for Children 4th edition.

Separate models created for each sum of metabolites ($\Sigma\text{DEHP}$, $\Sigma\text{HMW}$, $\Sigma\text{LMW}$).

($+$) Higher scores indicate poorer performance/more symptomatic behavior; ($-$) lower scores indicate poorer performance/more symptomatic behavior.

NEPSY tower measured at one time point and modeled using linear regression.

Data also presented in [Figure 1](#f1){ref-type="fig"}.

Cognition {#s3.2}
---------

We found mostly null associations of prenatal $\Sigma\text{LMW}$, $\Sigma\text{HMW}$, and $\Sigma\text{DEHP}$ concentrations with IQ scores in analyses of boys and girls combined ([Table 3](#t3){ref-type="table"}). However, when we stratified by child's sex, we observed that higher prenatal $\Sigma\text{HMW}$ concentrations were associated with lower FSIQ ($\beta = - 1.9$, 95% CI: $- 4.1$, 0.3) and WMIQ ($\beta = - 2.1$, 95% CI: $- 4.2$, 0.0) scores among boys but higher FSIQ, WMIQ, and PSIQ scores among girls ($\beta = 1.8$, 95% CI: 0.1, 3.3; $\beta = 1.8$, 95% CI: 0.1, 3.4; and $\beta = 1.5$, 95% CI: 0.2, 2.9; respectively; all $p\text{-int} < 0.10$; see [Figure 1](#f1){ref-type="fig"} and Table S12). Similarly, higher $\Sigma\text{DEHP}$ concentrations were associated with decreased WMIQ scores in boys ($\beta = - 1.9$, 95% CI: $- 3.9$, 0.1) and increased FSIQ, WMIQ, and PSIQ scores among girls ($\beta = 1.6$, 95% CI: 0.0, 3.2; $\beta = 1.6$, 95% CI: 0.1, 3.2; and $\beta = 1.5$, 95% CI: 0.1, 2.8; respectively; all $p\text{-int} < 0.10$; see [Figure 1](#f1){ref-type="fig"} and Table S12). Among all children, MEP concentrations were associated with slightly decreased WMIQ scores ($\beta = - 0.6$, 95% CI: $- 1.3$, 0.1) and MiBP concentrations were associated with slightly increased PSIQ scores ($\beta = 0.9$, 95% CI: 0.0, 1.8; see Table S13). Effect estimates for VCIQ were null for all metabolites in both stratified and sex-stratified analyses ([Table 3](#t3){ref-type="table"}, Table S12, Table S13).

![Adjusted associations \[$\beta$ (95% CI)\] for WISC-IV IQ scores per 2-fold increase in prenatal (A) $\Sigma\text{LMW}$, (B) $\Sigma\text{HMW}$, and (C) $\Sigma\text{DEHP}$ concentrations (nmol/mL; $\log_{2}\text{-transformed}$ and specific gravity-adjusted) among all children and stratified by sex using GEE models. Models adjusted for maternal age at enrollment, education, country of birth, years in the United States, depression at time of assessment; child sex, child age at time of assessment, language of assessment, HOME score, and household income at time of assessment. Sex-specific effect estimates and *p*-int values obtained from models including cross-product terms between child sex and the exposure and child sex and each of the covariates. *p*-int represents interaction of exposure and sex obtained from these models. Data also shown in [Tables 3](#t3){ref-type="table"} and S12.](ehp-127-107010-g001){#f1}

Social Cognition {#s3.3}
----------------

Most associations of prenatal phthalate concentrations with social cognition outcomes hovered at the null in both combined and sex-stratified analyses. Higher $\Sigma\text{DEHP}$ concentrations were associated with slightly better scores on the ENI assessment at 9 y among all children ($\beta = 0.1$, 95% CI: 0.0, 0.2; see [Table 4](#t4){ref-type="table"}) and among girls ($\beta = 0.2$, 95% CI: 0.0, 0.4; see Table S14).

###### 

Adjusted associations \[$\beta$ (95% CI)\] of prenatal urinary phthalate biomarker concentrations (nmol/mL; $\log_{2}\text{-transformed}$ and specific gravity-adjusted)[^*a*^](#TF15){ref-type="table-fn"} with behavior and social cognition outcomes at 7, 9, 10.5, 12, 14, and/or 16 y using GEE models, CHAMACOS.

Table 4 has seven columns, namely, outcomes, orientation, n values, k values, sigma LMW, sigma HMW, and sigma DEHP.

  Outcomes                                                                 Orientation[^*b*^](#TF16){ref-type="table-fn"}   $n$     *k*   $\Sigma\text{LMW}$       $\Sigma\text{HMW}$       $\Sigma\text{DEHP}$
  ------------------------------------------------------------------------ ------------------------------------------------ ------- ----- ------------------------ ------------------------ ------------------------
  *Social cognition*[^*c*^](#TF17){ref-type="table-fn"}                                                                                                                                     
  SRS Total Score (14 y)                                                   ($+$)                                            245     245   0.4 ($- 0.2$, 0.9)       $- 0.3$ ($- 1.1$, 0.5)   $- 0.3$ ($- 1.1$, 0.5)
  ENI (9 y)                                                                ($-$)                                            313     313   0.0 ($- 0.1$, 0.1)       0.1 ($- 0.1$, 0.2)       0.1 (0.0, 0.2)
  NEPSY-II (12 y)                                                          ($-$)                                            310     310   $- 0.1$ ($- 0.3$, 0.2)   $- 0.3$ ($- 0.7$, 0.1)   $- 0.2$ ($- 0.5$, 0.2)
  *Behavior*                                                                                                                                                                                
  BASC-2---parent-report (*T*-score)                                                                                                                                                        
   Internalizing problems (7, 10.5, 14, 16 y)                              ($+$)                                            1,226   328   0.4 ($- 0.1$, 1.0)       0.5 ($- 0.4$, 1.4)       0.4 ($- 0.5$,1.2)
    Depression scale[^*c*^](#TF17){ref-type="table-fn"} (7 y)              ($+$)                                            322     322   0.4 ($- 0.1$, 1.0)       0.4 ($- 0.5$, 1.3)       0.3 ($- 0.6$, 1.1)
    Anxiety scale[^*c*^](#TF17){ref-type="table-fn"} (7 y)                 ($+$)                                            313     313   0.3 ($- 0.3$, 1.0)       0.8 ($- 0.4$, 1.9)       0.6 ($- 0.5$, 1.7)
   Externalizing problems (7, 10.5, 14, 16 y)                              ($+$)                                            1,219   328   0.1 ($- 0.4$, 0.5)       0.2 ($- 0.6$, 0.9)       0.1 ($- 0.6$, 0.7)
    Hyperactivity scale (7, 10.5, 14, 16 y)                                ($+$)                                            1,226   328   0.0 ($- 0.4$, 0.4)       $- 0.1$ ($- 0.7$, 0.6)   $- 0.1$ ($- 0.8$, 0.5)
    Attention problems scale (7, 10.5, 14, 16 y)                           ($+$)                                            1,226   328   0.0 ($- 0.5$, 0.5)       $- 0.1$ ($- 1.0$, 0.7)   $- 0.1$ ($- 0.9$, 0.7)
  BASC-2---teacher-report (*T*-score)[^*c*^](#TF17){ref-type="table-fn"}                                                                                                                    
   Internalizing problems (7 y)                                            ($+$)                                            265     265   $- 0.7$ ($- 1.6$, 0.2)   $- 0.4$ ($- 1.8$, 1.0)   $- 0.3$ ($- 1.6$, 1.0)
    Depression scale (7 y)                                                 ($+$)                                            265     265   $- 0.6$ ($- 1.4$, 0.1)   $- 0.2$ ($- 1.4$, 0.9)   $- 0.2$ ($- 1.4$, 0.9)
    Anxiety scale (7 y)                                                    ($+$)                                            265     265   $- 0.9$ ($- 1.8$, 0.1)   $- 0.8$ ($- 2.1$, 0.5)   $- 0.7$ ($- 2.0$, 0.6)
   Externalizing problems (7 y)                                            ($+$)                                            265     265   $- 0.1$ ($- 0.8$, 0.6)   0.0 ($- 1.0$, 1.0)       0.2 ($- 0.7$, 1.1)
    Hyperactivity scale (7 y)                                              ($+$)                                            265     265   0.0 ($- 0.7$, 0.7)       $- 0.2$ ($- 1.4$, 0.9)   $- 0.1$ ($- 1.1$, 0.9)
    Attention problems scale (7 y)                                         ($+$)                                            265     265   0.2 ($- 0.8$, 0.4)       $- 0.5$ ($- 1.4$, 0.4)   $- 0.3$ ($- 1.2$, 0.5)
  CADS---parent-report (*T*-score)                                                                                                                                                          
   ADHD Index (7, 9, 12 y)                                                 ($+$)                                            920     332   $- 0.3$ ($- 0.7$, 0.1)   $- 0.2$ ($- 1.0$, 0.5)   $- 0.2$ ($- 1.0$, 0.5)
   DSM-IV Total Scale (7, 9, 12 y)                                         ($+$)                                            921     332   $- 0.3$ ($- 0.7$, 0.1)   $- 0.1$ ($- 1.0$, 0.7)   $- 0.2$ ($- 1.0$, 0.5)
    Inattentive scale (7, 9, 12 y)                                         ($+$)                                            920     332   $- 0.3$ ($- 0.7$, 0.1)   $- 0.3$ ($- 1.0$, 0.5)   $- 0.3$ ($- 0.9$, 0.4)
    Hyperactive/impulsive scale (7, 9, 12 y)                               ($+$)                                            920     332   $- 0.2$ ($- 0.7$, 0.2)   0.0 ($- 0.9$, 0.9)       $- 0.1$ ($- 1.0$, 0.7)
  CADS---teacher-report (*T*-score)[^*c*^](#TF17){ref-type="table-fn"}                                                                                                                      
   ADHD Index (7 y)                                                        ($+$)                                            261     261   $- 0.4$ ($- 1.2$, 0.5)   $- 0.5$ ($- 1.9$, 0.9)   $- 0.4$ ($- 1.6$, 0.9)
   DSM-IV Total Scale (7 y)                                                ($+$)                                            260     260   $- 0.2$ ($- 0.9$, 0.5)   $- 0.2$ ($- 1.4$, 1.0)   $- 0.1$ ($- 1.2$, 1.0)
    Inattentive scale (7 y)                                                ($+$)                                            264     264   $- 0.1$ ($- 0.8$, 0.5)   $- 0.1$ ($- 1.2$, 0.9)   $- 0.1$ ($- 1.0$, 0.9)
    Hyperactive/impulsive scale (7 y)                                      ($+$)                                            264     264   $- 0.1$ ($- 0.8$, 0.6)   0.1 ($- 1.1$, 1.3)       0.2 ($- 0.9$, 1.3)
  CPT-II (*T*-score)                                                                                                                                                                        
   Errors of omission (9, 12 y)                                            ($+$)                                            595     317   0.9 (0.0, 1.8)           $- 0.1$ ($- 1.2$, 1.1)   $- 0.2$ ($- 1.2$, 0.9)
   Errors of commission (9, 12 y)                                          ($+$)                                            595     317   0.3 ($- 0.2$, 0.8)       $- 0.1$ ($- 1.0$, 0.8)   $- 0.3$ ($- 1.1$, 0.6)
   ADHD confidence index (9, 12 y)                                         ($+$)                                            596     317   0.7 ($- 0.5$, 1.9)       $- 1.0$ ($- 2.7$, 0.8)   $- 1.0$ ($- 2.6$, 0.6)

Note: Models were adjusted for maternal age at enrollment, education, country of birth, years in the U.S., depression at time of assessment; child sex, child age at time of assessment, language of assessment, HOME score, and household income at time of assessment. CPT-II models were also adjusted for children's video game usage at time of assessment. ADHD, Attention Deficit Hyperactivity Disorder; BASC-2, Behavior Assessment System for Children, 2nd edition; CADS, Conners\' ADHD/DSM-IV Scales; CPT-II, Continuous Performance Test, 2nd edition; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, 4th edition; ENI, Evaluación Neuropsicológica del Niño; *k*, number of children with data for at least one time point; $n$, number of observations from all time points; NEPSY-II, A Developmental Neuropsychological Assessment, 2nd Edition; $\Sigma\text{LMW}$, sum of metabolites of low-molecular-weight phthalates; $\Sigma\text{HMW}$, sum of metabolites of high-molecular-weight phthalates; $\Sigma\text{DEHP}$, sum of di(2-ethylhexyl) phthalate metabolites. SRS, Social Responsiveness Scale, version 2.

Separate models created for each sum of metabolites ($\Sigma\text{DEHP}$, $\Sigma\text{HMW}$, $\Sigma\text{LMW}$).

($+$) Higher scores indicate poorer performance/more symptomatic behavior; ($-$) lower scores indicate poorer performance/more symptomatic behavior.

Measured at one time point and modeled using linear regression.

Behavior {#s3.4}
--------

Among all children, higher prenatal $\Sigma\text{LMW}$ phthalate concentrations were associated with more errors of omission (higher *T*-scores) on the performance-based CPT-II ($\beta = 0.9$; 95% CI: 0.0, 1.8) measured at 9 and 12 y ([Table 4](#t4){ref-type="table"}) and poorer self-reported behaviors measured using the BASC-2 SRP scale, including more hyperactivity ($\beta = 0.8$; 95% CI: 0.1, 1.4), attention problems ($\beta = 1.5$; 95% CI: 0.7, 2.2), anxiety ($\beta = 0.9$; 95% CI: 0.0, 1.8), and overall internalizing problems on the composite scale ($\beta = 1.2$; 95% CI: 0.4, 1.9) measured at 16 y ([Table 5](#t5){ref-type="table"}). Similar, albeit weaker, trends were observed for parent-reported BASC-2 results modeled using GE; however, associations of phthalates with most teacher-reported behaviors were null or in the opposite direction of parent- and self-reported results ([Table 4](#t4){ref-type="table"}). We did not observe consistent sex-specific associations for behavior outcomes in GEE (Table S14) or linear regression models (Table S15). Prenatal MEP, MBzP, MCPP, and MCOP concentrations were associated with increased scores for parent-reported internalizing problems and/or errors of commission (Table S16). Similarly, prenatal concentrations of MEP and MCPP were associated with increased self-reported internalizing problems at age 16 (Table S17).

###### 

Adjusted associations \[$\beta$ (95% CI)\] of prenatal urinary phthalate biomarker concentrations (nmol/mL; $\log_{2}\text{-transformed}$ and specific gravity-adjusted)[^*a*^](#TF19){ref-type="table-fn"} with self-reported BASC-2 behavioral outcomes at 10.5, 14, and 16 y using linear regression models, CHAMACOS.

Table 5 has seven columns, namely, outcomes, orientation, n values, k values, sigma LMW, sigma HMW, and sigma DEHP.

  Outcome                      Orientation[^*b*^](#TF20){ref-type="table-fn"}   $n$   $\Sigma\text{LMW}$       $\Sigma\text{HMW}$       $\Sigma\text{DEHP}$
  ---------------------------- ------------------------------------------------ ----- ------------------------ ------------------------ ------------------------
  10.5-y assessment                                                                                                                     
   Internalizing problems      ($+$)                                            ---   ---                      ---                      ---
    Depression scale           ($+$)                                            289   0.5 ($- 0.1$, 1.1)       0.7 ($- 0.5$, 1.9)       0.6 ($- 0.5$, 1.8)
    Anxiety scale              ($+$)                                            289   0.3 ($- 0.3$, 1.0)       0.5 ($- 0.6$, 1.5)       0.4 ($- 0.6$, 1.4)
   Externalizing problems                                                                                                               
    Hyperactivity scale        ($+$)                                            299   0.2 ($- 0.5$, 0.8)       0.5 ($- 0.6$, 1.5)       0.3 ($- 0.7$, 1.3)
    Attention problems scale   ($+$)                                            290   $- 0.1$ ($- 0.8$, 0.7)   $- 0.4$ ($- 1.5$, 0.8)   $- 0.4$ ($- 1.4$, 0.7)
  14-y assessment                                                                                                                       
   Internalizing problems      ($+$)                                            ---   ---                      ---                      ---
    Depression scale           ($+$)                                            301   0.5 ($- 0.1$, 1.2)       0.6 ($- 0.6$, 1.8)       0.5 ($- 0.6$, 1.6)
    Anxiety scale              ($+$)                                            300   0.4 ($- 0.2$, 1.1)       $- 0.3$ ($- 1.3$, 0.7)   $- 0.4$ ($- 1.3$, 0.6)
   Externalizing problems                                                                                                               
    Hyperactivity scale        ($+$)                                            ---   ---                      ---                      ---
    Attention problems scale   ($+$)                                            ---   ---                      ---                      ---
  16-y assessment                                                                                                                       
   Internalizing problems      ($+$)                                            283   1.2 (0.4, 1.9)           0.4 ($- 0.7$, 1.4)       0.4 ($- 0.6$, 1.3)
    Depression scale           ($+$)                                            286   0.7 ($- 0.1$, 1.5)       0.2 ($- 0.8$, 1.2)       0.3 ($- 0.7$, 1.2)
    Anxiety scale              ($+$)                                            286   0.9 (0.0, 1.8)           0.7 ($- 0.4$, 1.8)       0.6 ($- 0.5$, 1.7)
   Externalizing problems                                                                                                               
    Hyperactivity scale        ($+$)                                            285   0.8 (0.1, 1.4)           0.0 ($- 1.0$, 1.0)       $- 0.2$ ($- 1.2$, 0.8)
    Attention problems scale   ($+$)                                            286   1.5 (0.7, 2.2)           $- 0.2$ ($- 1.2$, 0.8)   $- 0.3$ ($- 1.2$, 0.6)

Note: Models were adjusted for maternal age at enrollment, education, country of birth, years in the U.S., depression at time of assessment; ---, no data; child sex, child age at time of assessment, language of assessment, HOME score, and household income at time of assessment. BASC-2, Behavior Assessment System for Children, 2nd edition; $n$, number of children; $\Sigma\text{LMW}$, sum of metabolites of low-molecular-weight phthalates; $\Sigma\text{HMW}$, sum of metabolites of high-molecular-weight phthalates; $\Sigma\text{DEHP}$, sum of di(2-ethylhexyl) phthalate metabolites.

Separate models created for each sum of metabolites ($\Sigma\text{DEHP}$, $\Sigma\text{HMW}$, $\Sigma\text{LMW}$).

($+$) Higher scores indicate poorer performance/more symptomatic behavior; ($-$) lower scores indicate poorer performance/more symptomatic behavior.

Sensitivity Analyses {#s3.5}
--------------------

In general, the point estimates did not change appreciably in sensitivity analyses after *a*) excluding preterm births and LBW children (see Tables S18--S20), and *b*) adjusting for additional potential confounders, including maternal receptive vocabulary (see Tables S21--S23) and breastfeeding duration (see Tables S24--S26). Associations of prenatal $\Sigma\text{LMW}$ phthalate concentrations with self-reported hyperactivity, depression, and anxiety were attenuated in models adjusted for coexposure to PBDEs (Tables S27--S29), OP and OC pesticides (Tables S30--S35), and Mn (Tables S36-38), with all CI including the null.

Discussion {#s4}
==========

In this prospective cohort of low-income Mexican-American children, we observed primarily null associations of prenatal urinary phthalate biomarker concentrations with a wide range of measures of childhood and adolescent cognition and behavior. We did find suggestive associations of prenatal $\Sigma\text{LMW}$ phthalates with more parent- and self-reported internalizing problems and poorer scores on performance-based behavioral assessments (i.e., CPT-II errors of omission). We also observed that prenatal $\Sigma\text{HMW}$ and $\Sigma\text{DEHP}$ concentrations were associated with slightly higher IQ scores among girls and lower IQ scores among boys.

The previous literature from longitudinal birth cohort studies evaluating prenatal phthalate exposure and childhood neurodevelopment has produced mixed results. With respect to cognitive function, the Columbia Center for Children's Environmental Health (CCCEH) study reported that prenatal concentrations of the LMW phthalate metabolites MBzP and MiBP were inversely associated with IQ scores among 328 children age 7 y ([@c31]). Conversely, the Health Outcomes and Measures of the Environment (HOME) study found that higher prenatal concentrations of LMW phthalate metabolites, including MBzP and MBP, were associated with improved performance on the Virtual Morris Water Maze among 198 8-y-old children, particularly among boys ([@c11]). We also found evidence of better cognition in association with higher prenatal phthalate exposure in sex-stratified analyses in CHAMACOS; however, we observed that prenatal $\Sigma\text{HMW}$ and $\Sigma\text{DEHP}$ concentrations were associated with slightly higher IQ scores among girls and lower IQ scores among boys.

Only one previous study, the Mount Sinai Children's Environmental Healthy study, examined associations of prenatal phthalate exposure with executive function and found that higher $\Sigma\text{LMW}$ metabolite concentrations from third-trimester maternal urine were associated with poorer BRIEF global executive composite index scores in 188 children ages 4--9 y ([@c26]). In contrast, we found null associations for phthalates and BRIEF behavioral regulation and global executive composite scores, and slightly better scores on the parent-reported BRIEF metacognition index.

Three previous studies have reported associations of prenatal phthalates with more externalizing behaviors, including aggression, hyperactivity, and conduct problems ([@c26]; [@c44]; [@c48]). The Mount Sinai study reported associations of prenatal LMW phthalate concentrations with parent report of increased aggression, attention, and conduct problems on the BASC among children ages 4--9 y ([@c26]). A study of 122 mother--child pairs in Taiwan found that prenatal concentrations of LMW phthalate metabolites, as well as DEHP metabolites, were associated with parent report of more aggressive and delinquent behaviors on the Child Behavior Checklist (CBCL) at 8 y ([@c48]). In the multicenter Study for Future Families of 153 children ages 6 to 10 y in 4 U.S. states, prenatal MBP, a LMW phthalate, was associated with more parent-reported inattention, rule-breaking behavior, aggression, and conduct problems on the CBCL ([@c44]). In addition, prenatal MBzP, a HMW phthalate, was associated with more parent-reported oppositional and conduct problems, but only among boys ([@c44]). Only the Spanish INfancia y Medio Ambiente (INMA)-Sabadell birth cohort study ($n = 367$) found essentially null associations for prenatal phthalate biomarkers and all behavioral outcomes, including ADHD-related behaviors, measured at 4 and 7 y ([@c33]). In the CHAMACOS study, we observed modest associations of $\Sigma\text{LMW}$ phthalates with attention problems, including poorer performance on the CPT-II at ages 9 and 12 and more symptomatic self-reported BASC-2 hyperactivity and attention problems scores at age 16. Associations with all other externalizing behaviors, including those from teacher-, parent-, and self-report, were essentially null.

Results from previous studies are less consistent with respect to internalizing behaviors. Although the Mount Sinai study reported associations of prenatal $\Sigma\text{LMW}$ phthalate concentrations with more anxiety and depression among all children ([@c26]), the Study for Future Families found associations with less anxiety among girls ([@c44]), and the Taiwanese study reported null associations for prenatal phthalates with all internalizing behaviors ([@c48]). Furthermore, the CCCEH study reported associations of prenatal MBP and MBzP concentrations (metabolites of LMW phthalates) with more internalizing behaviors among all children, with stronger associations observed for MBzP among girls ([@c74]). Associations of prenatal $\Sigma\text{LMW}$ phthalates and BASC self-report of internalizing behaviors at age 16 were among the strongest in the CHAMACOS study, though associations with BASC parent report were considerably weaker, and BASC teacher-report associations were in the opposite direction. Although these results may seem paradoxical, they are largely in line with previous studies that have reported poor multiple informant agreement for parent-, teacher-, and child-reported behaviors, with worse concordance among participants with internalizing disorders ([@c54]; [@c70]). Although externalizing problems may be more easily observed by others, a child can choose not to disclose feelings of anxiety or depression to teachers or caregivers ([@c62]). Previous studies indicate that teacher--youth agreement may be less than parent--youth agreement ([@c76]), particularly for internalizing disorders ([@c62]), which is largely consistent with findings from our study. We observed the strongest findings for self-reported behavior at age 16, and evidence suggests that discrepancies in parent- and self-report and the reliability of self-reported behaviors increase with age ([@c24]; [@c70]). Although reports from multiple informants provide a more comprehensive picture of behaviors of children and adolescents throughout time, adolescents may be a more reliable source about their own internalizing behavior.

Consistent with the results from a study of 201 children age 3 y from the Markers of Autism Risk in Babies---Learning Early Signs (MARBLES) cohort ([@c64]), a study of 175 children ages 4--5 y from the HOME cohort ([@c12]), and the Spanish INMA-Sabadell birth cohort ([@c33]), we found null associations of prenatal phthalate exposure with social cognition outcomes. In contrast, a study of 137 children ages 7--9 y from the Mount Sinai cohort found that higher prenatal $\Sigma\text{LMW}$ phthalate concentrations were associated with poorer SRS scores ([@c55]). To our knowledge, ours is the first study to investigate phthalate-related associations with tests of affect recognition (i.e., ENI and NEPSY-II), which may provide more comprehensive and objective data than parent-report alone.

Potential reasons for the heterogeneity in our findings and those from previous studies include differences in *a*) sample size, *b*) timing and number of prenatal exposure measurements, *c*) specific phthalate metabolites measured, *d*) neurodevelopmental tests administered, *e*) age of child at neurodevelopmental assessments, and *f*) sociodemographic characteristics that may influence phthalate exposure. For example, we assessed a larger diversity of neurodevelopmental outcomes than many previous studies assessed, and ours is the only study to examine associations of prenatal phthalates exposure with behavior and executive function using computer-based assessments. Additionally, we had a larger sample size than those in some previous investigations and assessed phthalate exposure from two prenatal urine samples, whereas many previous studies relied on one measurement. Notably, some of our strongest findings were for self-reported behavioral outcomes at age 16, and to our knowledge, ours is the first study to examine associations of prenatal phthalate exposure and neurodevelopment past age 10 y.

Our study has several strengths and limitations. The longitudinal design of CHAMACOS and collection of rich data, including biological specimens, a wide array of neurodevelopmental measures, behavioral measures from multiple reporters (e.g., parents, teachers, and participants), and covariates, allowed for a very thorough and nuanced examination of the potential impacts of *in utero* phthalate exposure throughout childhood and adolescence. Ours is the first study to our knowledge to investigate the impacts of prenatal phthalate exposure and neurocognitive outcomes during adolescence, allowing us to examine the persistence of effects identified in cohorts of younger children. In addition, although previous studies have relied solely on parent-report of executive function, behavior, and social cognition, we directly assessed participants with respect to executive function (WCST and NEPSY Tower), attention and impulse control (CPT-II), and social cognition (ENI and NEPSY Affect Recognition). These arguably more objective, performance-based tests contribute to the richness of our neurodevelopmental assessments. Furthermore, to our knowledge, we are the first longitudinal study to examine the effects of prenatal phthalate exposure on adolescent self-reported behavior, which may provide more nuanced information on internalizing behaviors such as anxiety and depression.

Although the collection of rich neurodevelopmental data across various domains is a primary strength of our study, it also makes interpretation of our results more difficult, as demonstrated by inconsistency in our findings across these multiple outcomes. More important, we conducted a large number of analyses with multiple comparisons, which could produce spurious associations by chance alone. Therefore, we were careful to report patterns in our results rather than highlighting isolated findings. Overall, the richness and diversity of our outcomes allow us to conclude with some confidence that prenatal exposure to select phthalates is not strongly associated with neurodevelopment in our cohort.

The prenatal period has been identified as the most vulnerable window of neurotoxicity ([@c49]); however, emerging evidence indicates that childhood phthalate exposure may be associated with adverse cognitive outcomes among children ages 2 to 12 y ([@c17]; [@c31]; [@c41]; [@c43]; [@c47]). We did not measure childhood phthalate concentrations in our cohort, and it is possible that postnatal exposures could affect neurodevelopment in this population, particularly during puberty, a period during which the brain is developing rapidly and may be particularly susceptible to EDCs ([@c71]). Previous research has shown sex-specific changes in internalizing and externalizing behaviors, executive function, and social cognition during puberty ([@c6]; [@c36]; [@c67]), and a toxicology study found that DEHP exposure during puberty was associated with increased anxiety among female mice ([@c71]). In addition to prenatal exposures, future studies should consider also assessing phthalate concentrations during childhood and adolescence to identify critical periods of susceptibility.

Our study and others have shown relatively low correlation between phthalate measurements collected at multiple times during pregnancy ([@c33]) and poor reproducibility between measurements ([@c42]). Other studies have also suggested that phthalate metabolite concentrations can vary depending on the time of day at which the urine sample was collected ([@c65]) and that exposure biomarker patterns may vary, depending on the primary source of phthalate exposure ([@c42]; [@c57]). In addition to introducing nondifferential exposure misclassification that may have biased our results toward the null, the nonpersistent nature of phthalates makes it difficult to identify windows of susceptibility based on the timing of prenatal exposure ([@c12]). Future research investigating these exposure--outcome relationships should include a more critical evaluation of the most robust sampling strategy ([@c63]) (i.e., spot, first morning void, 24-h collection) to reduce exposure measurement error for the phthalate metabolite of interest.

Overall, we found mostly null associations of prenatal phthalate exposure with child and adolescent neurodevelopmental outcomes in the CHAMACOS cohort, though we observed some suggestive associations of prenatal LMW phthalate biomarker concentrations with more internalizing and externalizing behaviors, particularly from self-reported and performance-based assessments. These findings add to a growing literature addressing the potential developmental neurotoxicity of phthalate exposure.
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